创伤性脑损伤诱导的体温调节障碍:β受体阻滞剂的作用是什么?
该研究为基于MIMIC数据库的回顾性队列分析,纳入头部AIS≥3且其他部位AIS<2、发生创伤性高热(至少一次T>38.3°C且血、尿、肺泡灌洗液微生物培养阴性)的危重TBI患者,排除伤前使用β受体阻滞剂者。经1:1倾向评分匹配后共1544例(β受体阻滞剂组772例,主要为美托洛尔60%、普萘洛尔25%、阿替洛尔15%;对照组772例)。β受体阻滞剂组发热次数更少(8次 vs 12次,p=0.003)、最高体温更低(38.0°C vs 38.5°C,p=0.025)、发热间隔更长(3小时 vs 1小时,p=0.013)。线性回归显示普萘洛尔在减少发热次数和降低最高体温方面更优,但三种β受体阻滞剂在延长发热间隔方面无显著差异(p=0.582)。
要点
- 纳入标准:头部AIS≥3、其他部位AIS<2的危重TBI患者,发生至少一次T>38.3°C且血、尿、肺泡灌洗液培养阴性的创伤性高热。
- 排除伤前已使用β受体阻滞剂者;匹配后β受体阻滞剂组772例 vs 对照组772例。
- β受体阻滞剂组发热次数更少(8次 vs 12次,p=0.003),最高体温更低(38.0°C vs 38.5°C,p=0.025)。
- β受体阻滞剂组发热间隔更长(3小时 vs 1小时,p=0.013)。
- 线性回归显示普萘洛尔在减少发热次数和降低最高体温方面优于美托洛尔和阿替洛尔,但三者延长发热间隔无差异(p=0.582)。
适用人群与场景
- 危重TBI患者,头部AIS评分≥3且其他体区AIS评分<2,发生创伤性高热(至少一次T>38.3°C且血、尿、肺泡灌洗液微生物培养阴性)。
- 排除伤前已使用β受体阻滞剂的患者。
诊断标准与关键阈值
- 创伤性高热定义:至少一次发热发作(T>38.3°C)且微生物培养(血、尿、支气管肺泡灌洗液)阴性。
- 头部AIS评分≥3,其他体区AIS评分<2。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性队列分析,基于Medical Information Mart for Intensive Care数据库。
- 样本量:分析4286例危重TBI患者,经1:1倾向评分匹配后获得1544例匹配队列(β受体阻滞剂组772例,对照组772例)。
- 人群特征:平均年龄63.4±15.4岁,头部AIS中位数3(3-4),损伤严重度评分中位数10(9-16)。
- β受体阻滞剂组成:美托洛尔60%,普萘洛尔25%,阿替洛尔15%。
- 主要结局:β受体阻滞剂组发热次数更少(8次 vs 12次,p=0.003),最高体温更低(38.0°C vs 38.5°C,p=0.025),发热间隔更长(3小时 vs 1小时,p=0.013)。
- 线性回归:普萘洛尔在减少发热次数和降低最高体温方面更优;三种β受体阻滞剂在延长发热间隔方面无显著差异(p=0.582)。
证据类型、等级与局限
- 证据类型:回顾性队列研究( Therapeutic, level IV)。
- 局限:回顾性设计、基于数据库的二次分析,原文未提及其他局限。
对床旁实践的改变
- 对于头部AIS≥3且其他部位AIS<2、发生培养阴性的创伤性高热的危重TBI患者,β受体阻滞剂可能减少发热次数、降低最高体温并延长发热间隔。
- 普萘洛尔在减少发热次数和降低最高体温方面可能优于美托洛尔和阿替洛尔,但三种药物在延长发热间隔方面无差异。
- 该证据为回顾性 level IV,不能作为常规推荐,需前瞻性验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury (TBI) is associated with sympathetic discharge that leads to posttraumatic hyperthermia (PTH). Beta blockers (ββ) are known to counteract overactive sympathetic discharge. The aim of our study was to evaluate the effect of ββ on PTH in critically-ill TBI patients.
METHODS: We performed retrospective cohort analysis of the Medical Information Mart for Intensive Care database. We included all critically ill TBI patients with head Abbreviated Injury Scale (AIS) score of 3 or greater and other body region AIS score less than 2 who developed PTH (at least one febrile episode [T > 38.3°C] with negative microbiological cultures (blood, urine, and bronchoalveolar lavage). Patients on preinjury ββ were excluded. Patients were stratified into (ββ+) and (ββ-) groups. Propensity score matching was performed (1:1 ratio) controlling for patient demographics, injury parameters and other medications that influence temperature. Outcomes were the number of febrile episodes, maximum temperature, and the time interval between febrile episodes. Multivariate linear regression was performed.
RESULTS: We analyzed 4,286 critically ill TBI patients. A matched cohort of 1,544 patients was obtained: 772 ββ + (metoprolol, 60%; propranolol, 25%; and atenolol, 15%) and 772 ββ-. Mean age was 63.4 ± 15.4 years, median head AIS score of 3 (3-4), and median Injury Severity Score of 10 (9-16). Patients in the ββ+ group had a lower number of febrile episodes (8 episodes vs. 12 episodes; p = 0.003), lower median maximum temperature (38.0°C vs. 38.5°C; p = 0.025), and a longer median time between febrile episodes (3 hours vs. 1 hour; p = 0.013). On linear regression, propranolol was found to be superior in terms of reducing the number of febrile episodes and the maximum temperature. However, there was no significant difference between the three ββ in terms of reducing the time interval between febrile episodes (p = 0.582).
CONCLUSION: Beta blockers attenuate PTH by decreasing the frequency of febrile episodes, increasing the time interval between febrile episodes, and reducing the maximum rise in temperature. ββ may be a potential therapeutic modality in PTH.
LEVEL OF EVIDENCE: Therapeutic, level IV.
参考来源
- Asmar S, Bible L, Chehab M, et al. Traumatic brain injury induced temperature dysregulation: What is the role of β blockers? J Trauma Acute Care Surg. 2021. PMID: 33332783. doi:10.1097/TA.0000000000002975
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。